.png){kind=icon}
Return
Thyroid Cancer
.png){kind=icon}
PRE
AI
DOI：10.1001/jama.2023.26348.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Importance Approximately 43 720 new cases of thyroid carcinoma are expected to be diagnosed in 2023 in the US. Five-year relative survival is approximately 98.5%. This review summarizes current evidence regarding pathophysiology, diagnosis, and management of early-stage and advanced thyroid cancer. Observations Papillary thyroid cancer accounts for approximately 84% of all thyroid cancers. Papillary, follicular (approximate to 4%), and oncocytic (approximate to 2%) forms arise from thyroid follicular cells and are termed well-differentiated thyroid cancer. Aggressive forms of follicular cell-derived thyroid cancer are poorly differentiated thyroid cancer (approximate to 5%) and anaplastic thyroid cancer (approximate to 1%). Medullary thyroid cancer (approximate to 4%) arises from parafollicular C cells. Most cases of well-differentiated thyroid cancer are asymptomatic and detected during physical examination or incidentally found on diagnostic imaging studies. For microcarcinomas (<= 1 cm), observation without surgical resection can be considered. For tumors larger than 1 cm with or without lymph node metastases, surgery with or without radioactive iodine is curative in most cases. Surgical resection is the preferred approach for patients with recurrent locoregional disease. For metastatic disease, surgical resection or stereotactic body irradiation is favored over systemic therapy (eg, lenvatinib, dabrafenib). Antiangiogenic multikinase inhibitors (eg, sorafenib, lenvatinib, cabozantinib) are approved for thyroid cancer that does not respond to radioactive iodine, with response rates 12% to 65%. Targeted therapies such as dabrafenib and selpercatinib are directed to genetic mutations (BRAF, RET, NTRK, MEK) that give rise to thyroid cancer and are used in patients with advanced thyroid carcinoma. Conclusions Approximately 44 000 new cases of thyroid cancer are diagnosed each year in the US, with a 5-year relative survival of 98.5%. Surgery is curative in most cases of well-differentiated thyroid cancer. Radioactive iodine treatment after surgery improves overall survival in patients at high risk of recurrence. Antiangiogenic multikinase inhibitors and targeted therapies to genetic mutations that give rise to thyroid cancer are increasingly used in the treatment of metastatic disease.
Keywords:
ASSOCIATION GUIDELINES
RADIOACTIVE IODINE
DOUBLE-BLIND
FOLLOW-UP
GENOMIC CHARACTERIZATION
THYROTROPIN SUPPRESSION
MOLECULAR-GENETICS
TASK-FORCE
RADIOIODINE
CARCINOMA
Journal
J
IF:
55
Papers:
4.1W
Citations:
19.4W
Organization
View more organizations
Cited Papers
ShareSaveShareSaveReassessing surgical guidelines for papillary thyroid cancer impact on survival: Expanding indications for lobectomy.png)
SURGERY
OAAI
SURGERYIF2.7
OAAIShareSaveShareSaveShareSave View more